MedPath

Comparison of hypotensive effect and prevention to progression of diabetic nephrolopathy with Olmesartan and Ca channel blocker in patient of type 2 diabetic

Not Applicable
Conditions
hypertension with type 2 diabetis
Registration Number
JPRN-UMIN000004253
Lead Sponsor
Endcrinology and Diabetis,Saitama Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
150
Inclusion Criteria

Not provided

Exclusion Criteria

patient of 1)RAS inhibitor with Ca channel Blocker 2)except from 20 to 80 years old 3)SBP less than 130mmHg or DBP less than 80mmHg 4)HbA1c over 8.0% 5)S-Cr over 2.5mg/dL 6)hypersensitivity to drug in object 7)inadequate with Doctor's decision

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Office blood pressure , Albumin-Creatinin Ratio , Serum-Creatinin Consentration
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath